Exacerbation Risk in Asthma

NCT ID: NCT05501639

Last Updated: 2024-04-01

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1899 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-14

Study Completion Date

2021-11-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to conduct a comparative analysis of patients using Tiotropium in combination with Inhaled Corticosteroids (ICS) versus those that use long-acting β2-agonists (LABA) medication in combination with ICS.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

tiotropium + inhaled corticosteroids (ICS) group

tiotropium

Intervention Type DRUG

tiotropium

inhaled corticosteroids (ICS)

Intervention Type DRUG

inhaled corticosteroids (ICS)

long-acting β2-agonists (LABA) + inhaled corticosteroids (ICS) group

long-acting β2-agonists (LABA)

Intervention Type DRUG

long-acting β2-agonists (LABA)

inhaled corticosteroids (ICS)

Intervention Type DRUG

inhaled corticosteroids (ICS)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tiotropium

tiotropium

Intervention Type DRUG

long-acting β2-agonists (LABA)

long-acting β2-agonists (LABA)

Intervention Type DRUG

inhaled corticosteroids (ICS)

inhaled corticosteroids (ICS)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with least two asthma diagnosis
* Patients will be required to be concurrently on inhaled corticosteroids (ICS)+Tiotropium (tio) (specifically Tiotropium Respimat® 1.25 mcg) or ICS/LABA
* Patients will be required to have enrollment for at least 6 months prior to ICS+Tio or ICS/LABA use

Exclusion Criteria

* Patients with least two diagnosis of chronic obstructive pulmonary disease (COPD) at any time during the study period
* Patients less than 12 years of age
* Patients on biologics within 6 months prior to ICS+Tio or ICS/LABA use
* Patients with prior Tio or ICS/LABA use during the 6-month baseline period
* Patients with urinary bladder obstruction, urinary retention, and glaucoma
* After the propensity score matching (PSM) process, unmatched patients
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

eMax Health

White Plains, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0205-0547

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Steroids In Eosinophil Negative Asthma
NCT02066298 COMPLETED PHASE3